When viral oncoprotein meets tumor suppressor: a structural view
نویسندگان
چکیده
منابع مشابه
When viral oncoprotein meets tumor suppressor: a structural view.
In 1898, Friedrich Loeffler and Paul Frosch reported on the identification of a filterable agent that was the cause of foot and mouth disease in livestock (Levine 2001). This was the first identification of a vertebrate virus, shortly after the isolation of the tobacco mosaic virus by Dimitrii Ivanovsky in 1892 (Horzinek 1997). Since these initial discoveries, we have come to appreciate how the...
متن کاملIntestinal Regeneration: YAP—Tumor Suppressor and Oncoprotein?
The Hippo signaling pathway exerts a growth-suppressive effect by inhibitory phosphorylation of the oncogenic transcription co-activator Yki/YAP. A recent study paradoxically reports that genetic removal of YAP enhances intestinal stem cell expansion and regeneration.
متن کاملCancer genetics: Tumor suppressor meets oncogene
The adenomatous polyposis coli (APC) tumor suppressor protein is inactivated by mutations in the majority of colorectal cancers. A recent study has revealed that alterations in the APC signaling pathway can result in the transcriptional activation of the c-MYC gene.
متن کاملWhen biochemistry meets structural biology: the cautionary tale of EmrE.
When biochemistry meets structural biology a more complete understanding of the mechanism of biological macromolecules is usually achieved. Several high-resolution structures of ion-coupled transporters have enriched the understanding of mechanisms of substrate recognition, translocation and coupling of substrate fluxes. However, two X-ray structures of EmrE, the smallest ion-coupled multi-drug...
متن کاملProteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein.
Eph receptor tyrosine kinases are considered candidate therapeutic targets in cancer, but they can exert opposing effects on cell growth. In the presence of its ligands, Eph receptor EphA2 suppresses signaling by other growth factor receptors, including ErbB, whereas ligand-independent activation of EphA2 augments ErbB signaling. To deploy EphA2-targeting drugs effectively in tumors, the anti-o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Genes & Development
سال: 2006
ISSN: 0890-9369
DOI: 10.1101/gad.1471706